Optiflow™
Flow Matters

Keeping you up-to-date with emerging nasal high flow (NHF) clinical evidence and practice guidelines. 


Latest edition  Subscribe
Evidence is published weekly demonstrating the impact of NHF on improved patient care and outcomes. More than 600 studies have alreay been published this year.*

Updated Edition - March 2023


Early use of NHF in infants and children 

In this update we review the literature with the addition of the PARIS 2 trial and provide an evidence-based approach to implementation of NHF in pediatric patients.
 

Download PDF

Share PDF via email
 

Evidence-based clinical practice guidelines




Hundreds of randomized controlled trials have been consolidated into clinical practice guidelines. 

These guidelines underscore the breadth of application of nasal high flow therapy.

We’ve created a table that will help you review the  guidelines by patient population and application.

 

Interactive table 

Evidence-based guidelines recommend the use of NHF for COVID-19 patients 

Read about this and research related to airborne transmission.

Read online


Download PDF

Share

LinkedIn  Twitter

ROX Index - a bedside tool for monitoring patients on NHF

The validated ROX index uses just 3 data points to provide an indicator of outcomes in adults with AHRF receiving NHF therapy.


Author: Stanislav Taktov, M.D., Ph.D.

Read online


Download PDF

Share

LinkedIn  Twitter

Subscribe to Flow Matters
If you have an enquiry about our products, please provide the following information so a Fisher & Paykel Healthcare representative can contact you. For further details on how this information will be used, see below or go to our privacy statement.
Enter security code:*
 Security code